These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32869945)

  • 1. Cancer immunotherapy trial design with long-term survivors.
    Ding X; Wu J
    Pharm Stat; 2021 Jan; 20(1):117-128. PubMed ID: 32869945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
    Chu C; Liu S; Rong A
    Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
    Wei J; Wu J
    Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
    Liu S; Chu C; Rong A
    Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
    Wu J; Wei J
    Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
    Wang Z; Zhang Q; Xue A; Whitmore J
    Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size calculation for the proportional hazards cure model.
    Wang S; Zhang J; Lu W
    Stat Med; 2012 Dec; 31(29):3959-71. PubMed ID: 22786805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.
    Ding X; Wu J
    Pharm Stat; 2020 Jul; 19(4):424-435. PubMed ID: 32090453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy trial design with delayed treatment effect.
    Wu J; Wei J
    Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
    Wu J; Li Y; Zhu L
    J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size calculation for mixture cure model with restricted mean survival time as a primary endpoint.
    Li Z; Geng X; Hou Y; Chen Z
    Stat Methods Med Res; 2024 Sep; 33(9):1546-1558. PubMed ID: 39106345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical and practical considerations in designing of immuno-oncology trials.
    Mukhopadhyay P; Huang W; Metcalfe P; Öhrn F; Jenner M; Stone A
    J Biopharm Stat; 2020 Nov; 30(6):1130-1146. PubMed ID: 33706684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
    Ye T; Yu M
    Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex survival trial design by the product integration method.
    Tang Y
    Stat Med; 2022 Feb; 41(4):798-814. PubMed ID: 34908180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect.
    Yu C; Huang X; Nian H; He P
    Pharm Stat; 2021 May; 20(3):528-550. PubMed ID: 33427400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Inverse Log-Rank Test: A Versatile Procedure for Late Separating Survival Curves.
    Efird JT
    Int J Environ Res Public Health; 2023 Dec; 20(24):. PubMed ID: 38131716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials.
    Kaneko Y; Morita S
    J Biopharm Stat; 2024 Aug; 34(5):626-645. PubMed ID: 37585719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
    Wu J
    J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.